Analyst Justin Zelin of BTIG maintained a Buy rating on Jasper Therapeutics, retaining the price target of $7.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Justin Zelin has given his Buy rating due to a combination of factors that reinforce confidence in Jasper Therapeutics’ drug product, briquilimab. The resolution of the BEACON Cohort 8/9 anomaly, which was attributed to patient misdiagnosis rather than issues with the drug itself, has restored faith in the drug’s mechanism. This was supported by consistent pharmacokinetic and pharmacodynamic data across different drug lots and sites, and a key opinion leader panel confirmed that most non-responders did not have mast-cell-driven conditions, aligning with known misdiagnosis rates in the field.
Additionally, Jasper’s early proof-of-concept data in asthma showed promising results, with significant improvements in various clinical measures following a single dose of briquilimab. This suggests potential for the drug to effectively target lung mast cells and alter inflammatory responses, making it an attractive candidate for further development in the large and diverse asthma market. The company’s strategic plans, including upcoming data releases and potential partnerships, also contribute to the positive outlook, with significant developments expected in early 2026.
Zelin covers the Healthcare sector, focusing on stocks such as NovaBridge Biosciences, Viking Therapeutics, and Jasper Therapeutics. According to TipRanks, Zelin has an average return of 8.0% and a 38.08% success rate on recommended stocks.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.